Skip to content

Total Assets at other companies

Amgen logo
AmgenAMGN
$92.5B+3.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$40.87B+8.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
CG Oncology logo
CG OncologyCGON
$1.14B+55.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
$461.23M-2.1%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total assets?
Replimune Group (REPL) reported total assets of $333.59M in Q4 2025.
How has Replimune Group's total assets changed year-over-year?
Replimune Group's total assets decreased by 44.7% year-over-year, from $603.63M to $333.59M.
What is the long-term trend for Replimune Group's total assets?
Over 4 years (2021 to 2025), Replimune Group's total assets has grown at a 0.4% compound annual growth rate (CAGR), from $543.1M to $551.33M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.